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INTRODUCTION {#hbm22486-sec-0001}
============

Premenstrual dysphoric disorder (PMDD) is categorized as a mood disorder \[APA, [2013](#hbm22486-bib-0002){ref-type="ref"}\] with onset of functionally impairing or distressing mood and physical symptoms in the luteal phase of the menstrual cycle, a decline in symptom severity after onset of menstruation, and an absence of symptoms in the postmenstrual week \[Yonkers et al., [2008](#hbm22486-bib-0053){ref-type="ref"}\]. Hallmark mood symptoms include mood lability, irritability, anxiety, tension, and depression \[Epperson et al., [2012](#hbm22486-bib-0012){ref-type="ref"}\]. The disorder affects roughly 5% of women of reproductive age \[Wittchen et al., [2002](#hbm22486-bib-0052){ref-type="ref"}\], and has a moderate heritability \[Kendler et al., [1998](#hbm22486-bib-0026){ref-type="ref"}\]. However, no abnormality in peripheral levels of ovarian hormones has been observed \[Yonkers et al., [2008](#hbm22486-bib-0053){ref-type="ref"}\], and no genetic marker has consistently been associated with PMDD. The neurobiological underpinnings of PMDD thus remain largely unknown.

Ovarian hormones have profound organizational effects during brain development, and important and diverse activational effects in adulthood \[Cahill, [2006](#hbm22486-bib-0005){ref-type="ref"}; Gillies and McArthur, [2010](#hbm22486-bib-0018){ref-type="ref"}; Savic, [2010](#hbm22486-bib-0042){ref-type="ref"}\]. Neuroimaging findings in PMDD suggest menstrual cycle phase‐by‐diagnosis interaction effects, indeed highlighting the relevance of hormone fluctuations in this disorder \[Epperson, [2013](#hbm22486-bib-0009){ref-type="ref"}\]. Moreover, a proton magnetic resonance spectroscopy (^1^H‐MRS) study implicated a gamma‐aminobutyric acid (GABA) interaction with ovarian hormones and neurosteroids in the pathophysiology of PMDD \[Epperson et al., [2002](#hbm22486-bib-0011){ref-type="ref"}\], and a PET study suggested a role for serotonin in PMDD \[Jovanovic et al., [2006](#hbm22486-bib-0025){ref-type="ref"}\].

Emotions drive cognitive and behavioral processes, and are biologically basic and inherited states \[Lindquist et al., [2012](#hbm22486-bib-0029){ref-type="ref"}\]. The functional neuroanatomy of emotion processing and response comprises mainly the amygdala, medial PFC, and insular cortex \[Etkin et al., [2011](#hbm22486-bib-0013){ref-type="ref"}; Shin and Liberzon, [2010](#hbm22486-bib-0044){ref-type="ref"}\]. The medial PFC and ACC have been linked to sadness, anxiety and depressive states \[Etkin et al., [2011](#hbm22486-bib-0013){ref-type="ref"}; Lindquist et al., [2012](#hbm22486-bib-0029){ref-type="ref"}\], typical symptomatic characteristics of PMDD. The ACC, in particular the pregenual region (pgACC) and the ventro‐medial PFC (vmPFC), are involved in the top‐down regulation of anxiety, through inhibition of amygdala reactivity to stressful stimuli; and deficient pregenual‐prefrontal functioning and amygdala hyper‐responsiveness are typical characteristics of anxiety disorders (Rauch *et al*, [2006](#hbm22486-bib-0041){ref-type="ref"}). Interestingly, patients with PMDD have increased amygdala activation in response to emotional stimuli \[Gingnell et al., [2012](#hbm22486-bib-0020){ref-type="ref"}; Protopopescu et al., [2008](#hbm22486-bib-0040){ref-type="ref"}\], suggesting an impaired anxiety regulation. In addition, patients with PMDD, who have high scores of anxiety, display increased emotion‐induced amygdala reactivity in the luteal phase \[Gingnell et al., [2012](#hbm22486-bib-0020){ref-type="ref"}\].

Association studies of PMDD have indicated markers in genes related to the monoamine and sex gonadal hormone systems \[Adams and McCrone, [2012](#hbm22486-bib-0001){ref-type="ref"}; Dhingra et al., [2007](#hbm22486-bib-0007){ref-type="ref"}; Gingnell et al., [2010](#hbm22486-bib-0019){ref-type="ref"}; Huo et al., [2007](#hbm22486-bib-0024){ref-type="ref"}\]. Selective serotonin reuptake inhibitors (SSRIs) are the first‐line treatment for PMDD, and patients preferentially respond to serotonergic rather than noradrenergic antidepressants \[Freeman et al., [1999](#hbm22486-bib-0015){ref-type="ref"}\]. Complementary to the serotonin (5‐HT) system is the brain derived neurotrophic factor (BDNF). A constellation of molecular, pharmacological and genetic findings support an interaction between 5‐HT and BDNF with implication for mood disorders \[Martinowich and Lu, [2008](#hbm22486-bib-0030){ref-type="ref"}\]. A mouse and a human model provided translational evidence of impaired extinction of fear among carriers of the Met allele, a phenotype that is associated with anxious and depressive behavior \[Soliman et al., [2010](#hbm22486-bib-0048){ref-type="ref"}\]. More recently one study of mice, making use of a genetic knock‐in animal model, provided evidence of an association between the *BDNF* Met66 allele and anxiety‐related behavior during the estrous phase, when both estradiol and progesterone decline \[Bath et al., [2012](#hbm22486-bib-0004){ref-type="ref"}\]. All together these findings make these two functional polymorphisms, the *5‐HT* linked polymorphic region (5‐HTTLPR) and the single nucleotide polymorphism (SNP) adenine/guanine (A/G), Valine66Methionine (Val66Met), *BDNF* (rs6265), candidate genetic markers for PMDD. It is thus plausible that the 5‐HTTLPR and BDNF Val66Met are potential modulator**s** of pregenual‐prefrontal region reactivity to emotional stimuli in PMDD.

While there is a growing literature demonstrating an effect of menstrual cycle phase and/or ovarian hormones in neuroimaging of PMDD, no previous study has considered genetic factors in relation to emotional areas with regulatory functions such as pgACC and vmPFC. Hence, the present study aimed to investigate whether pregenual‐prefrontal activation during emotion processing is lower in patients with PMDD than in healthy controls in the late luteal phases of the menstrual cycle. The study also aimed to elucidate the potential mediating effect of the functional polymorphisms 5‐HTTLPR and *BDNF* Val66Met on pregenual‐prefrontal activation.

MATERIALS AND METHODS {#hbm22486-sec-0002}
=====================

Participants {#hbm22486-sec-0003}
------------

The study sample included 31 patients with PMDD and 31 healthy controls with regular menstrual cycles (25--31 days). Included patients met the criteria for a PMDD diagnosis, as defined by DSM‐IV TR, and they were recruited among women seeking help for premenstrual symptoms at the out‐patient ward of the Department of Obstetrics and Gynecology, Uppsala University Hospital or from newspaper advertisement. Diagnosis was based on daily, prospective symptom ratings on the cyclicity diagnoser (CD) scale during two consecutive menstrual cycles \[Sundstrom et al., [1999](#hbm22486-bib-0050){ref-type="ref"}\]. The scale consists of nine negative mood symptoms (depression, decreased interest in usual activities, fatigue, irritability, tension, mood swings, lability, difficulties in concentrating, and sleeping disturbances), two positive mood symptoms (cheerfulness and energy), four somatic symptoms (food cravings, swelling, breast tenderness, and menstrual bleeding), and one parameter for measuring impact on daily life. The CD scale is a Likert scale ranging from 0 to 8 with 0 indicating a complete absence of the symptom and eight maximal severity of the symptom. Patients were considered to have PMDD if they had a clinically relevant 100% increase in five symptoms (at least one of them being one of the core symptoms) during seven premenstrual days compared to seven mid‐follicular days, associated with a significant social or occupational impairment \[Hammarbäck et al., [1989](#hbm22486-bib-0021){ref-type="ref"}\]. All patients displayed at least 1 week of sparse symptoms (mean scores \<2) in the follicular phase. The controls were physically healthy women with no self‐reported premenstrual symptoms. They displayed no luteal phase symptoms (mean scores \<2), no significant cyclicity (\<50% increase) in affective symptoms between the follicular and luteal phases, and no functional impairment according to the CD scale.

Exclusion criteria for all participants were pregnancy; breast feeding; treatment with hormonal contraceptives; benzodiazepines or other psychotropic drugs (including SSRI) within 3 months prior to inclusion; previous brain surgery; visual impairment (\>5 degrees myopic/hyperopic or profound astigmatism); and profound fear of confined spaces. Participants with on‐going depression, anxiety, or other psychiatric disorders were excluded using the Swedish version of the Mini International Neuropsychiatric Interview (M.I.N.I) \[Sheehan et al., [1998](#hbm22486-bib-0043){ref-type="ref"}\]. All participants provided written informed consent prior to inclusion, and the procedures were approved by the Regional Ethical Review Board, Uppsala, Sweden.

Neuroimaging Study Design {#hbm22486-sec-0004}
-------------------------

A subset including 16 patients and 15 controls, all right‐handed, participated in two fMRI sessions, once in the mid‐follicular phase (6--12 days after onset of menstruation) and once in the late luteal phase (postovulatory day 8--13). Data on 14 out of the 16 PMDD patients and all controls have previously been presented in a ROI‐based approach focusing on the amygdale \[Gingnell et al., [2012](#hbm22486-bib-0020){ref-type="ref"}\].

Late luteal phase testing was scheduled according to the positive luteinizing hormone (LH) assay (Clearplan, Unipath, Bedford, UK), and was verified with progesterone serum concentrations and onset of the next menstrual bleeding. The luteal phase interval was chosen to correspond with maximum severity of mood symptoms rather than peak progesterone levels. To avoid test order effects across the menstrual cycle, half of the participants were scheduled to start in the follicular phase, while the remaining participants entered the study in the late luteal phase.

Hormonal Analyses {#hbm22486-sec-0005}
-----------------

Serum progesterone and estradiol levels were measured before each scanning session and were analyzed by competitive immunometry electrochemistry luminescence detection at the accredited Clinical Chemistry Laboratory, Uppsala University Hospital. The samples were run on a Roche Cobas e601 with Cobas Elecsys progesterone or estradiol reagent kits (Roche Diagnostics, Bromma, Sweden). For progesterone the measurement interval was 0.1--191 nmol l^−1^ and for estradiol 18.4--15,781 pmol l^−1^. The progesterone intra‐assay coefficient of variation was 2.2% at 2.4 nmol l^−1^ and 2.8% at 31.6 nmol l^−1^, while the estradiol intra‐assay coefficient of variation was 6.8% at 85.5 pmol l^−1^ and 2.8% at 1640 pmol l^−1^.

Experimental Paradigm {#hbm22486-sec-0006}
---------------------

The emotion processing task used in this study has been previously described \[Hariri et al., [2002](#hbm22486-bib-0022){ref-type="ref"}\]. Briefly, participants viewed images of faces displaying angry or fearful emotions (emotion task) or vertical/horizontal ellipses (sensorimotor control task) displayed in blocks of six. All images consisted of three photos or geometrical figures ordered in a triangle, one on top and two below (Supporting Information Fig. 1). For each task, subjects were instructed to compare the top image with the two images below and decide which one displayed the same facial expression, alternatively the same geometrical orientation, as the top image. Subjects answered by pressing a button with the left or right index finger. Each emotion block had an equal mix of target and nontarget emotions as well as sex of the actors. Images were presented for 4 s and were interspaced with a fixation cross (2 s for the sensorimotor control tasks and randomly selected 2, 4, or 6 s for the emotion task).

fMRI Data Acquisition and Analysis {#hbm22486-sec-0007}
----------------------------------

MR imaging was performed according to standard procedures. MR imaging was performed using a 3T whole body scanner (Achieva 3T X Philips scanner, Philips Medical Systems, Best, The Netherlands) equipped with an eight‐channel head coil. An anatomical T1‐weighted reference data set to a voxel size of 0.8 × 1.0 × 2.0 mm^3^ and 60 slices was acquired at the beginning of each scanning session. During stimulus presentation BOLD imaging was performed using a single shot EPI sequence with parameters TE/TR 35/3,000 ms, flip angle 90°, acquisition matrix 76 × 77, acquired voxel size 3.0 × 3.0 × 3.0 mm^3^ and 30 slices.

Subjects were lying on their back in the scanner with the head lightly fixated with Velcro strips. During scanning, visual stimuli were presented through goggles mounted on the head coil (VisualSystem, NordicNeuroLab, Bergen, Norway). The stimulus paradigm was implemented using the commercial software package E‐prime (Psychology Software Tools, Sharpsburg, PA). To synchronize the paradigm and the MR‐scanner, trigger pulses from the scanner were fed to the paradigm‐controlling PC through SyncBox (NordicNeuroLab, Bergen, Norway).

All image processing and data analysis was conducted using Statistical Parametric Mapping (SPM8) implemented in MATLAB using default parameters, unless specified otherwise. The pre‐processing steps, which were independent of previous analyses \[Gingnell et al., [2012](#hbm22486-bib-0020){ref-type="ref"}\], included slice timing correction (reference = middle slice) \[Sladky et al., [2011](#hbm22486-bib-0045){ref-type="ref"}\], movement correction (reference = mean image), as well as spatial normalization to an EPI‐template in stereotactic space as defined by the Montreal Neurological Institute (MNI). Spatial smoothing was applied with a Gaussian kernel of 8 × 8 × 8 mm^3^ full‐width at half‐maximum. Single subject activation maps were computed with the general linear model in SPM8. Here, one regressor for each condition (emotion and sensorimotor) was convolved with the default hemodynamic response function. The realignment parameters obtained from the motion correction were used as nuisance regressors in the first‐level analysis. For the contrast of interest used in the group analyses the individual difference between emotional vs. sensorimotor condition was computed.

Genetic Analyses {#hbm22486-sec-0008}
----------------

DNA was isolated from blood and used to genotype 5‐HTTLPR and *BDNF* Val66Met polymorphisms with standard methods. DNA was isolated from blood samples using QIAamp DNA Mini Kit (<http://www.qiagen.com/>). The 5‐HTTLPR and *BDNF* Val66Met were genotyped. The 5‐HTTLPR was amplified using the following primer sequences: forward 5′‐AAC ATG CTC ATT TAA GAA GTG GAA C‐3′ and reverse 5′‐XCT AGA GGG ACT GAG CTG GAC AAC‐3′. The reverse primer was labeled with the fluorescent dye 5′‐hex. PCR was performed in a 10 μl reaction mixture containing DNA, 1.0 mM PCR 1xBuffer, 1.5 mM MgCl2, 0.2 mM dNTPs; 7%DMSO; 0.8 μM of two primers and 0.5 U Fast Start Taq DNA polymerase (Roche Diagnostics, Germany). The PCR reactions were performed on a GeneAmp 9700 (Applied Biosystems) at the following profile: starting at 94°C for 4 min, followed by 35 cycles of denaturation at 94°C for 45 s, annealing at 61°C for 1 min and elongation at 72°C for 90 s, with final extension at 72°C for 7 min. The PCR products were analyzed by capillary electrophoresis ABI PRISM\@3700 DNA Analyzer (Applied Biosystem, USA) and allele size were determined by manually checking the chromatograms using Gene Marker1.5® AFLP/Genotyping software (SoftGenetics LLC®2004. State College, PA). To estimate the rate of genotyping errors, one‐third of the sample has been analyzed twice and the PCR products were resolved by electrophoresis on a 2% agarose gel, run 1 h at 120 V, and visualized under UV light using SYBR ® Safe DNA Gel Stain (Invitrogen TM). Buffer used as a running buffer was 0.5 × Tris---EDTA‐Buffer (TEB) and sizes were determined by comparison with a 100 bp DNA sequencing ladder. No inconsistencies were identified. PCR was separately performed for *BDNF* Val66Met in a 5‐μl reaction mixture containing TaqMan®Universal PCR Master Mix (Applied Biosystems) 2.5 μl; 40× Custom TaqMan® SNP Genotyping Assays Mix (Applied Biosystems) 0.125 μl, and DNA. The Allele Discrimination PCR reaction was performed on an ABI PRISM®7900HT Sequence Detection System at the following thermal cycler conditions: initial step of 10 min at 95°C, followed by 40 cycles of 15 s at 92°C and of 60 s at 60°C. Genotypes were analyzed using SDS 2.3 (Applied Biosystem®). To estimate the rate of genotyping errors, the *BDNF* Val66Met polymorphism was amplified a second time using a fluorescence‐based competitive allele‐specific PCR (KASPar) assay (KBioscience, England) based on public genome sequence (<http://www.ensembl.org/>). Allele discrimination was done using SNPviewer2®. No inconsistencies were found. Genotypes of 5‐HTTLPR and *BDNF* Val66Met were in Hardy--Weinberg equilibrium (*P* = 1; and *P* = 0.30, respectively).

Psychiatric Symptoms {#hbm22486-sec-0009}
--------------------

The validated self‐rated Swedish version of the Montgomery---Åsberg depression rating scale (MADRS‐S) \[Montgomery and Asberg, [1979](#hbm22486-bib-0033){ref-type="ref"}\], and the Spielberger State‐Trait Anxiety Inventory---State version (STAI‐S) \[Hodgues and Spielberger, [1969](#hbm22486-bib-0023){ref-type="ref"}\] were used to assess depression and anxiety symptoms at each test day, once during the mid‐follicular and once during the late‐luteal phase. The trait version of the STAI (STAI‐T) \[Hodgues and Spielberger, [1969](#hbm22486-bib-0023){ref-type="ref"}\] was also administered.

Statistical Analyses {#hbm22486-sec-0010}
--------------------

For the functional MRI data, repeated‐measures analysis of variance (ANOVA) was done in SPM8 with menstrual cycle phase (within subject), subject (between subjects) and patient/control (between groups) as independent factors. Statistical inference was drawn at *P* \< 0.05 corrected for multiple comparisons with the family wise error rate (FWE) at cluster level following an uncorrected voxel level of *P* \< 0.001. The alpha‐thresholds for the region‐of‐interest (ROI) analysis, ANOVA test, was set to be *P* \< 0.05 since there was only one ROI (fronto‐cingulate cluster). Chi‐square or Mann--Whitney U‐tests were used to assess differences between groups regarding descriptive statistics; repeated measures ANOVA was used to test for differences in depression and anxiety symptoms by *BDNF* Val66Met and 5‐HTTLPR genotype between patients with PMDD and healthy controls. A three‐way repeated measure ANOVA of mean activation values of the fronto‐cingulate cluster was performed to test for group‐by‐phase‐by‐genotype interaction effects (IBM ® SPSS Statistics 20).

RESULTS {#hbm22486-sec-0011}
=======

Demographic characteristics suggest that the healthy controls were well matched to the PMDD patients. Description of demographic variables, reproductive history, and depressive‐ and anxiety symptoms is found in Supporting Information Table I. Genotype and allele frequencies of *BDNF* Val66Met and 5‐HTTLPR did not differ between PMDD patients and healthy controls (Supporting Information Table II). Estradiol and progesterone levels were in agreement with ovulatory cycles, and did not differ between PMDD patients and healthy controls (Supporting Information Table III). Depression and anxiety symptoms did not differ by *BDNF* Val66Met and 5‐HTTLPR genotypes in either the PMDD patients or healthy controls (Table [1](#hbm22486-tbl-0001){ref-type="table"}).

###### 

Depression and anxiety symptoms by *BDNF* Val66Met and 5‐HTTLPR genotype among patients with PMDD and healthy controls 1a

                                     Patients with PMDD (*n* = 31)   Healthy controls (*n* = 31)                                           
  ---------------------------------- ------------------------------- ----------------------------- --- ------------- ---- ------------ --- ------------
  MADRS follicular phase (score)     24                              5.75 (5.8)                    7   7.6 (6.8)     22   3.5 (3.3)    8   2.9 (1.8)
  MADRS luteal phase (score)         23                              12.0 (8.1)                    7   13.7 (10.4)   23   3.0 (3.0)    8   2.5 (2.0)
  STAI‐S folllicular phase (score)   24                              35.3 (8.7)                    7   32.3 (5.7)    21   29.9 (4.5)   8   29.3 (5.2)
  STAI‐S luteal phase (score)        23                              41.3 (10.5)                   7   43.4 (15.0)   22   29.6 (5.9)   8   29.1 (6.9)
  STAI‐T (score)                     14                              39.8 (16.3)                   4   36.0 (8.2)    11   31.4 (7.3)   4   25.5 (6.6)

                                     Patients with PMDD   Healthy controls                                                                               
  ---------------------------------- -------------------- ------------------ ---- ------------- --- ------------- --- ------------ ---- ------------ --- ------------
  MADRS follicular phase (score)     11                   7.5 (7.9)          12   5.0 (5.0)     8   6.0 (4.6)     6   2.5 (2.2)    19   3.3 (3.2)    5   4.6 (2.5)
  MADRS luteal phase (score)         10                   9.2 (6.3)          12   14.3 (8.2)    8   13.5 (11.1)   7   2.3 (2.2)    19   2.6 (2.9)    5   4.6 (2.7)
  STAI‐S folllicular phase (score)   11                   34.8 (7.8)         12   33.1 (7.3)    8   36.8 (10.2)   5   30.0 (4.0)   19   29.4 (4.0)   5   30.4 (7.8)
  STAI‐S luteal phase (score)        10                   37.1 (7.6)         12   44.2 (11.7)   8   44.1 (14.4)   6   28.5 (7.1)   19   29.7 (6.3)   5   29.8 (4.6)
  STAI‐T (score)                     5                    38.8 (16.8)        8    35.5 (17.5)   5   44.6 (6.2)    2   27.0 (9.9)   10   28.0 (6.1)   3   37.7 (6.5)

A: adenine; G: guanine; L: long; Met; methionine; S: short; Val: valine.

No difference in reaction time and accuracy were found between groups or cycle phases. Functional MRI analyses showed significant main effects for group and menstrual cycle phase but no significant group‐by‐phase interaction. More precisely, patients had decreased activation during the emotional discrimination task in the pregenual anterior cingulate cortex (pgACC) and the ventro‐medial prefrontal cortex (vmPFC), which was independent of menstrual phase (Figure [1](#hbm22486-fig-0001){ref-type="fig"}, Supporting Information Table IV). Further regions included the occipital and temporal lobes. On the other hand, patients exhibited increased activations in parietal and frontal regions as well as the supplementary motor area (Supporting Information Table IV). In addition, a main effect of menstrual phase was observed with the follicular phase being associated with higher activation in the motor cortex and the middle frontal gyrus compared to the luteal phase. No increased activations in the luteal phase were found (Supporting Information Table IV). In the present analysis on the whole‐brain level no significant difference was detected in the amygdale, which was present when using a hypothesis‐driven ROI approach \[Gingnell et al., [2012](#hbm22486-bib-0020){ref-type="ref"}\], thus indicating that differences between PMDD patients and controls are more pronounced in the fronto‐cingulate cortex than in the amygdale.

![Brain regions showing significantly different activation between PMDD patients and healthy controls during an emotion processing task independent of menstrual cycle phase. Decreased activations in PMDD subjects were found in the fronto‐cingulate cortex (peak *t* = −5.28 in the pregenual ACC). *P* \< 0.05 FWE‐corrected cluster level following *P* \< 0.001 uncorrected voxel level. Crosshair is at *x* / *y* / *z* = −2/40/4 mm MNI‐space. \[Color figure can be viewed in the online issue, which is available at <http://wileyonlinelibrary.com>.\]](HBM-35-4450-g001){#hbm22486-fig-0001}

Based on the *a priori* hypothesis from the literature and the present fMRI results concerning impaired functionality of the pregenual‐prefrontal region in PMDD patients, genetic influences were only tested in the fronto‐cingulate cluster. Post‐hoc functional ROI analyses in the fronto‐cingulate cluster of patients vs. controls showed no effect of 5‐HTTLPR genotype, but a genotype‐by‐group‐by‐phase interaction effect of *BDNF* Val66Met (df = 1, 27; *f* = 12.38; *P* = 0.002). The effect was present in the luteal phase, where PMDD patients carrying the BDNF Met allele (*N* = 4) had lower fronto‐cingulate cortex reactivity compared to the Met allele carrying controls (*N* = 4), Figure [2](#hbm22486-fig-0002){ref-type="fig"}. Adjustment for estradiol and/or progesterone levels did not change the results.

![Mean fronto‐cingulate cortex ROI activation in patients with PMDD and healthy comparison subjects during early follicular (left) and late luteal (right) phase by *BDNF* Val66Met genotype.](HBM-35-4450-g002){#hbm22486-fig-0002}

DISCUSSION {#hbm22486-sec-0012}
==========

Emotion Processing in PMDD {#hbm22486-sec-0013}
--------------------------

Women with PMDD had significantly lower, but phase‐independent, emotion‐induced fronto‐cingulate cortex activation in comparison with healthy controls. These findings are in line with a meta‐analysis in patients with generalized anxiety and/or major depressive disorders where impaired ventral ACC, and amygdala, activation was demonstrated \[Etkin and Schatzberg, [2011](#hbm22486-bib-0013){ref-type="ref"}\]. On the basis of the present data, previous ROI‐based studies in PMDD patients \[Gingnell et al., [2012](#hbm22486-bib-0020){ref-type="ref"}; Protopopescu et al., [2008](#hbm22486-bib-0040){ref-type="ref"}\], and patients with stress and anxiety disorders \[Rauch et al., [2006](#hbm22486-bib-0041){ref-type="ref"}; Shin and Liberzon, [2010](#hbm22486-bib-0044){ref-type="ref"}\], it is plausible that impaired functionality of the pregenual‐prefrontal region, and the amygdala, are characteristics of PMDD. However, longitudinal prospective studies are required to shed light on whether this is a risk factor or an acquired feature of the disorder.

Supportive evidence from genetic studies also points to the importance of the cingulate‐amygdala circuitry in affective disorders \[Pezawas et al., [2005](#hbm22486-bib-0037){ref-type="ref"}; Soliman et al., [2010](#hbm22486-bib-0048){ref-type="ref"}\]. The functional polymorphisms 5‐HTTLPR and *BDNF* Val66Met were, hence, evaluated in relation to the lowered emotion‐induced fronto‐cingulate cortex reactivity, and a phase‐dependent genotype‐by‐group interaction effect of *BDNF* Val66Met was found. Women with PMDD who were carriers of the Met allele had lower fronto‐cingulate cortex activation in the luteal phase compared to Met‐allele carrying controls.

A decade ago, an *in vitro* study and a knock‐in mice model of *BDNF* Val66Met provided convergent evidence that the Met allele leads to impaired activity‐dependent secretion, distribution to neuronal dendrites, and intracellular trafficking \[Chen et al., [2006](#hbm22486-bib-0006){ref-type="ref"}; Egan et al., [2003](#hbm22486-bib-0008){ref-type="ref"}\], and furthermore suggested that the Met allele is associated with anxiety‐like behavior and lack of responsiveness to SSRI \[Chen et al., [2006](#hbm22486-bib-0006){ref-type="ref"}\]. Later studies on BDNF in human anxiety and depression have confirmed these findings \[Martinowich et al., [2007](#hbm22486-bib-0031){ref-type="ref"}\]. Recently, Soliman et al. reported diminished vmPFC and elevated amygdala activity in *BDNF* Met carriers during fear extinction, a feature implicated in anxiety \[Soliman et al., [2010](#hbm22486-bib-0048){ref-type="ref"}\]. Additionally, neuroticism, which is a personality trait linked to PMDD \[Gingnell et al., [2010](#hbm22486-bib-0019){ref-type="ref"}\], has been associated with the *BDNF* Met allele, with low serum BDNF levels \[Lang et al., [2004](#hbm22486-bib-0027){ref-type="ref"}\], and with the 5‐HTTLPR S allele among women with PMDD \[Gingnell et al., [2010](#hbm22486-bib-0019){ref-type="ref"}\].

Moreover, a recent study on healthy women reported higher rostral ACC and amygdala activation during emotion processing in carriers of the BDNF Met allele and of the 5‐HTTLPR short allele, separately and in an epistatic mode, compared to other genotypes \[Outhred et al., [2012](#hbm22486-bib-0035){ref-type="ref"}\]. Our data partially confirm these findings, with healthy Met allele carrying subjects displaying enhanced fronto‐cingulate cortex activation only during the luteal phase. However, no effect was found for the 5‐HTTLPR, and interaction effects could not be tested in the present study due to the limited sample size. Thus the present results call for further investigation in larger case‐control samples.

In the present study women have been assessed during the late luteal phase of the menstrual cycle, which corresponds to the peak of symptoms and increased, but declining, progesterone levels \[Yonkers et al., [2008](#hbm22486-bib-0053){ref-type="ref"}\]. Thus, as the effect of the fronto‐cingulate cortex---*BDNF* Val66Met interaction is present in this time period, and disappears during the follicular phase, it is likely to be related to changes in progesterone levels. In fact, the effects of progesterone, which reaches its peak during the luteal phase to rapidly decrease at the end of the menstrual cycle and acts *via* the action of its metabolite allopregnanolone on GABA receptor A \[Backstrom et al., [2013](#hbm22486-bib-0003){ref-type="ref"}\], might be mediated by the direct or chloride pump‐mediated influence of BDNF on the GABAergic system. Additionally to the inhibition of the cation‐chloride transporter KCC2 by BDNF, estrogen enhances the cation‐chloride transporter NKCC1, thus leading to increased intracellular chloride and loss of GABA receptor A inhibitory effects \[Galanopoulou, [2008](#hbm22486-bib-0016){ref-type="ref"}; Nakamura et al., [2004](#hbm22486-bib-0034){ref-type="ref"}; Price et al., [2005](#hbm22486-bib-0039){ref-type="ref"}\]. However, somewhat complex bidirectional effects between BDNF and estrogen and progesterone impede further speculation and call for further molecular studies \[McNamara and Scharfman, [2012](#hbm22486-bib-0032){ref-type="ref"}\].

The *BDNF* Val66Met has been implicated in the sex differences of affective disorders \[Epperson and Bale, [2012](#hbm22486-bib-0012){ref-type="ref"}\], and as a biological link between sex hormones and BDNF \[Pluchino et al., [2013](#hbm22486-bib-0038){ref-type="ref"}\]. A putative estrogen response element in the *BDNF* gene has been suggested \[Sohrabji et al., [1995](#hbm22486-bib-0047){ref-type="ref"}\], but the mechanisms behind the interaction between sex hormones and BDNF remain largely unknown \[Sohrabji and Lewis, [2006](#hbm22486-bib-0046){ref-type="ref"}\]. Insights on the link between sex hormones and *BDNF* Val66Met, and its relevance to sex differences in affective disorders, predominantly come from rodent studies \[Epperson and Bale, [2012](#hbm22486-bib-0012){ref-type="ref"}\]. In fact, a region‐dependent influence of estrogen and progesterone on BDNF in the brain has been found in female rats \[Gibbs, [1999](#hbm22486-bib-0017){ref-type="ref"}\], and the *BDNF* Val66Met and estrous cycle stage interactive effect on hippocampal memory function and molecular markers of dendritic spine formation has been demonstrated in knock‐in mice \[Spencer et al., [2010](#hbm22486-bib-0049){ref-type="ref"}\]. More recently one study of mice, making use of a knock‐in animal model, provided evidence of an association between the Met allele and anxiety‐related behavior during the estrous stage, when both estradiol and progesterone levels decline \[Bath et al., [2012](#hbm22486-bib-0004){ref-type="ref"}\]. Interestingly, this phase corresponds to the late luteal phase in humans, and the timing of anxiety symptoms in mice matches with the peak of PMDD symptoms. All together, preclinical and clinical findings suggest the *BDNF* Met allele as a strong candidate for affective disorders with sex differences or those that are related to sex hormone changes, such as PMDD \[Epperson and Bale, [2012](#hbm22486-bib-0012){ref-type="ref"}\].

The present study furthers the understanding of a sex‐specific and sex hormone‐triggered affective disorder \[Yonkers et al., [2008](#hbm22486-bib-0053){ref-type="ref"}\] but the psychoneuroendocrine mechanism behind the present results needs to be investigated. If peripheral BDNF levels are related to *BDNF* Val66Met, and whether these two are related to central BDNF levels in different brain regions remains to be determined \[Gibbs, [1999](#hbm22486-bib-0017){ref-type="ref"}; Lang et al., [2009](#hbm22486-bib-0028){ref-type="ref"}; Ozan et al., [2010](#hbm22486-bib-0036){ref-type="ref"}\]. Furthermore, no effect of the 5‐HTTLPR was found in the present study. However, as 5‐HT and BDNF are two highly interlinked systems \[Martinowich and Lu, [2008](#hbm22486-bib-0030){ref-type="ref"}\], a role of 5‐HT in PMDD cannot be excluded. For instance the *BDNF* Met allele lower the sensitivity to 5‐HT signaling \[Martinowich and Lu, [2008](#hbm22486-bib-0030){ref-type="ref"}\], which may influence antidepressant efficacy in PMDD women. More, both systems carry out development and plasticity functions in the brain, and *BDNF* Val66Met and 5‐HTTLPR are likely to exert their influence at a neurotrophic level during development. Thus the present findings call also for further studies on the relation between sex hormones and neurotransmitters. Finally, no other study so far has investigated the *BDNF* Val66Met in PMDD, thus well‐powered genetic association studies are warranted.

CONCLUSIONS {#hbm22486-sec-0014}
===========

Altogether these findings lead to speculation that PMDD is characterized by impaired fronto‐cingulate cortex activation in response to emotions, and that the *BDNF* Val66Met polymorphism contributes to this association in the luteal phase. This is the first study investigating the interaction between emotional fronto‐cingulate activation in PMDD and the functional polymorphisms 5‐HTTLPR and *BDNF* Val66Met, thus contributing to the genetic dissection of women\'s mental health. Finally the finding on the *BDNF* Val66Met provides a pattern of association in line with preclinical findings \[Bath et al., [2012](#hbm22486-bib-0004){ref-type="ref"}\], and a translational attempt to investigate the neuropsychoendocrinology of PMDD. However the small sample size calls for independent replication of the genetic imaging findings.
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